Active Ingredient: Lanreotide
Lanreotide is indicated for the treatment of individuals with acromegaly when the circulating levels of Growth Hormone (GH) and/or Insulin-like Growth Factor-1 (IGF-1) remain abnormal after surgery and/or radiotherapy, or in patients who otherwise require medical treatment.
For this indication, competent medicine agencies globally authorize below treatments:
For:
Subcutaneous, between 60 milligrams lanreotide and 120 milligrams lanreotide, once every 28 days. The maximum allowed total dose is 120 milligrams lanreotide every 28 days.
The recommended starting dose is 60 mg to 120 mg administered every 28 days.
The dose may be varied according to the patient's response (judged by symptomatology and/or biochemical effect) or by the patient's possible experience with somatostatin analogues.
The dose should be individualised according to the response of the patient (as judged by a reduction in symptoms and/or a reduction in GH and/or IGF-1 levels).
For patients in whom clinical symptoms and biochemical parameters are not adequately controlled, the dose of lanreotide may be increased to a maximum of 120 mg at 28-day intervals.
If complete control is obtained (based on GH levels under 1 ng/ml, normalised IGF1 levels and/or disappearance of symptoms), the dose may be decreased.
Patients well controlled on a somatostatin analogue can alternatively be treated with lanreotide 120 mg every 42-56 days (6 to 8 weeks).
Long term monitoring of symptoms, GH and IGF-1 levels should be routinely carried out in all patients.
Lanreotide is administered by deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh.
For patients who receive a stable dose of lanreotide, and after appropriate training, the injection may be administered either by the patient or by a trained person. In case of self-injection, the injection should be given in the upper outer thigh.
The decision regarding administration by the patient or a trained person should be taken by a healthcare professional.
Regardless of the injection site, the skin should not be folded and the needle should be inserted rapidly and to its full length, perpendicularly to the skin.
The injection site should alternate between the right and left side.
For:
Regimen A :
Intramuscular, 30 milligrams lanreotide, once every 14 days.
Regimen B, in the case that there is absent response to treatment :
Intramuscular, 30 milligrams lanreotide, once every 14 days. Afterwards, intramuscular, 30 milligrams lanreotide, once every 7 to 10 days.
Initially, one intramuscular injection of 30 mg should be given every 14 days. The frequency of subsequent injections may be varied in accordance with the individual patient's response (as judged by a reduction in symptoms and/or a reduction in GH and/or IGF-1 levels) such that injections can be given every 7 to 10 days as necessary.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.